Anti-Asthma TDM Assay Kits Market - Regional Analysis
North America Market Insights
North America industry is set to hold largest revenue share by 2035.The growth of the market can be attributed majorly to the increasing count of patients suffering from asthma. A recent report published by the Asthma and Allergy Foundation of America states that approximately 25 million people living in the United States have asthma. On the other hand, the deteriorating quality of air in the region is expected to boost the market growth in the region. Research by the American Lung Association found that more than 135 million Americans breathe toxic air, putting their health and lives in danger.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of anti-asthma TDM assay kits is evaluated at USD 23.28 billion.
The global anti-asthma TDM assay kits market size exceeded USD 22.11 billion in 2025 and is set to expand at a CAGR of over 5.9%, surpassing USD 39.22 billion revenue by 2035.
North America is expected to command the largest share by 2035 in the anti-asthma TDM assay kits market, owing to the rising prevalence of asthma across the region.
Key players in the market include F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, Svar Life Science AB, Thermo Fisher Scientific Inc., Eagle Biosciences, Inc., Merck KGaA, Elabscience Biotechnology Inc., MyBioSource Inc., Creative Diagnostics, Diagnostic Automation (Cortez Diagnostics, Inc.).
